Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05708859 · ClinicalTrials.gov registry record · Phase 4
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
A Phase 4 study of Atherosclerosis and Type II Diabetes, sponsored by Matthew J. Budoff.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT05708859 is a Phase 4 study of Atherosclerosis and Type II Diabetes that is actively recruiting participants, run by Matthew J. Budoff. The registered enrollment target is 120 participants, below the 1,064-participant average among 69 other Atherosclerosis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05708859, a Phase 4 study of Atherosclerosis and Type II Diabetes, is actively recruiting participants, sponsored by Matthew J. Budoff.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
Study Locations (1)
California
- Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute) - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-01-02 |
| Est. Completion | 2026-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05708859
The ClinicalTrials.gov registry entry for NCT05708859 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,064-participant average among 69 other Atherosclerosis trials with a reported enrollment target (89% lower). The listed sponsor is Matthew J. Budoff, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atherosclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05708859 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05708859 about?
NCT05708859 is a clinical study titled "Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT". A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosc...
What is the current status of trial NCT05708859?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2024-01-02. Estimated completion is 2026-05.
What conditions does trial NCT05708859 study?
This clinical trial studies the following conditions: Atherosclerosis, Type II Diabetes.
What interventions are being tested in trial NCT05708859?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT05708859?
This trial is sponsored by Matthew J. Budoff, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05708859 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
RECRUITING · Phase 4
-
Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery
COMPLETED · Phase 4
-
Improving Cardiovascular Risk Prediction Using Hand Held Carotid Ultrasonography Study
COMPLETED · Phase 4
-
Testosterone Replacement in Older Men and Atherosclerosis Progression
COMPLETED · Phase 4
-
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
COMPLETED · Phase 4
-
Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.